Cargando…

Association between Menopausal Hormone Therapy and Frailty: Cross-Sectional Study Using National Survey Data in Korea

Frailty is a multidimensional clinical syndrome that increases the risk of adverse health outcomes. Previous studies have reported a close link between menopause and frailty. Combined estrogen–progestin therapy (or estrogen-only therapy in women who have undergone a hysterectomy) is currently approv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyunjoo, Lee, Euni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690075/
https://www.ncbi.nlm.nih.gov/pubmed/36360462
http://dx.doi.org/10.3390/healthcare10112121
_version_ 1784836695640768512
author Kim, Hyunjoo
Lee, Euni
author_facet Kim, Hyunjoo
Lee, Euni
author_sort Kim, Hyunjoo
collection PubMed
description Frailty is a multidimensional clinical syndrome that increases the risk of adverse health outcomes. Previous studies have reported a close link between menopause and frailty. Combined estrogen–progestin therapy (or estrogen-only therapy in women who have undergone a hysterectomy) is currently approved as a menopausal hormone therapy (MHT) to treat menopausal symptoms. Despite increasing evidence of the importance of sex hormones in the development of frailty, very few studies have investigated the association between MHT and frailty. A cross-sectional evaluation was conducted using population-based survey data known as the Korea National Health and Nutrition Examination Survey (KNHANES IV-V, 2008–2012). The KNHANES data provided variables that were used to construct a 51-item frailty index (FI). The number of study population, only including postmenopausal women, was 7823 women, and their mean age was 62.51 years (range 32–80 years). Approximately 40% of them had graduated from middle school or higher, 45% lived in metropolitan statistical areas, and 5% were recipients of the national Medical Aid. The mean age at menopause was 48.66 years (range 30–62 years). Overall, the mean FI value was 0.15, and the prevalence of MHT was 13.23%. Findings from multiple regression analysis using the inverse probability of treatment weighting showed that a treatment duration of more than 2 years and up to 5 years, age at first treatment between 50 and 59 years, and MHT initiation 3 to 6 years after menopause were all negatively associated with frailty (p < 0.05). Further studies are needed to confirm these findings using prospective data.
format Online
Article
Text
id pubmed-9690075
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96900752022-11-25 Association between Menopausal Hormone Therapy and Frailty: Cross-Sectional Study Using National Survey Data in Korea Kim, Hyunjoo Lee, Euni Healthcare (Basel) Article Frailty is a multidimensional clinical syndrome that increases the risk of adverse health outcomes. Previous studies have reported a close link between menopause and frailty. Combined estrogen–progestin therapy (or estrogen-only therapy in women who have undergone a hysterectomy) is currently approved as a menopausal hormone therapy (MHT) to treat menopausal symptoms. Despite increasing evidence of the importance of sex hormones in the development of frailty, very few studies have investigated the association between MHT and frailty. A cross-sectional evaluation was conducted using population-based survey data known as the Korea National Health and Nutrition Examination Survey (KNHANES IV-V, 2008–2012). The KNHANES data provided variables that were used to construct a 51-item frailty index (FI). The number of study population, only including postmenopausal women, was 7823 women, and their mean age was 62.51 years (range 32–80 years). Approximately 40% of them had graduated from middle school or higher, 45% lived in metropolitan statistical areas, and 5% were recipients of the national Medical Aid. The mean age at menopause was 48.66 years (range 30–62 years). Overall, the mean FI value was 0.15, and the prevalence of MHT was 13.23%. Findings from multiple regression analysis using the inverse probability of treatment weighting showed that a treatment duration of more than 2 years and up to 5 years, age at first treatment between 50 and 59 years, and MHT initiation 3 to 6 years after menopause were all negatively associated with frailty (p < 0.05). Further studies are needed to confirm these findings using prospective data. MDPI 2022-10-24 /pmc/articles/PMC9690075/ /pubmed/36360462 http://dx.doi.org/10.3390/healthcare10112121 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Hyunjoo
Lee, Euni
Association between Menopausal Hormone Therapy and Frailty: Cross-Sectional Study Using National Survey Data in Korea
title Association between Menopausal Hormone Therapy and Frailty: Cross-Sectional Study Using National Survey Data in Korea
title_full Association between Menopausal Hormone Therapy and Frailty: Cross-Sectional Study Using National Survey Data in Korea
title_fullStr Association between Menopausal Hormone Therapy and Frailty: Cross-Sectional Study Using National Survey Data in Korea
title_full_unstemmed Association between Menopausal Hormone Therapy and Frailty: Cross-Sectional Study Using National Survey Data in Korea
title_short Association between Menopausal Hormone Therapy and Frailty: Cross-Sectional Study Using National Survey Data in Korea
title_sort association between menopausal hormone therapy and frailty: cross-sectional study using national survey data in korea
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690075/
https://www.ncbi.nlm.nih.gov/pubmed/36360462
http://dx.doi.org/10.3390/healthcare10112121
work_keys_str_mv AT kimhyunjoo associationbetweenmenopausalhormonetherapyandfrailtycrosssectionalstudyusingnationalsurveydatainkorea
AT leeeuni associationbetweenmenopausalhormonetherapyandfrailtycrosssectionalstudyusingnationalsurveydatainkorea